Journal of Neurology

, Volume 253, Supplement 5, pp v50–v58 | Cite as

Intravenous immunoglobulins as therapeutic option in the treatment of multiple sclerosis



Treatment of neurological disorders with intravenous immunoglobulin (IVIG) is an increasing feature of practice for an expanding range of indications. This article reviews the current literature regarding the role of IVIG treatment in multiple sclerosis (MS) and summarizes recommendations for the use of IVIG in different courses and clinical subsets of the disease.

Principally based on the results of four randomized, double-blind, placebo-controlled trials (RCTs) and a corresponding meta-analysis, the amount of evidence for the efficacy of IVIG treatment is currently most convincing for the relapsing-remitting course of MS (RRMS); nevertheless, it lags clearly behind that for beta interferon due to smaller study sizes, partial deficits in study design and not established optimal dosage. This prompted the basis for a consensus statement in some countries to recommend IVIG as second-line treatment in RRMS, when other licensed therapies (i. e., beta interferon, glatiramer acetate) are individually not tolerated due to side effects or concomitant disease. Recent evidence indicates that IVIG is also effective in clinically isolated syndrome (CIS) and should be considered as a therapeutic option, particularly when licensed immunotherapy can not be offered. During an acute relapse additional IVIG administration to established steroid treatment showed no benefit. Despite promising experimental data on promotion of remyelination, fixed chronic deficits were not reversed or improved by long-term IVIG treatment either. Currently there is no indication for IVIG treatment in the chronic progressive disease stages, since a large and well-designed RCT failed to show any beneficial effect in patients with secondary progressive MS (SPMS) and data derived from primary progressive MS (PPMS) are still pending. However, preliminary results of a so far unpublished RCT including patients with PPMS and SPMS suggest a strong trend towards a beneficial effect in PPMS. So far, IVIG is the only therapy investigated for reducing postpartum relapses, whereas immunomodulatory drugs are contraindicated during pregnancy and lactation period. Data evaluating the peripartal use of IVIG along with the positive results of the trials in RRMS justify postpartal IVIG treatment particularly for mothers, who choose to breastfeed, under consideration of the recommendations specified for the relapsing-remitting disease course. As recently shown IVIG administration right from the early weeks of pregnancy appears to be a promising strategy, but cannot be recommended from the viewpoint of evidence-based medicine.

Key words

intravenous immunoglobulin clinically isolated syndrome relapsing-remitting MS chronic progressive MS remyelination 


  1. 1.
    Achiron A, Pras E, Gilad R, Ziv I, Mandel M, Gordon CR, Noy S, Sarova-Pinhas I, Melamed E (1992) Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting Multiple Sclerosis. Arch Neurol 49:1233–1236PubMedGoogle Scholar
  2. 2.
    Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, Elizur A, Goldhammer Y, Sarova-Pinhas I (1998) Intravenous immunoglobulin treatment in multiple sclerosis. Effect on relapses. Neurology 50:398–402PubMedGoogle Scholar
  3. 3.
    Achiron A, Kishner I, Dolev M, Stern Y, Dulitzky M, Schiff E, Achiron R (2004) Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol 251:1133–1137PubMedCrossRefGoogle Scholar
  4. 4.
    Achiron A, Kishner I, Sarova-Pinhas I, Raz H, Faibel M, Stern Y, Lavie M, Gurevich M, Dolev M, Magalashvili D, Barak Y (2004) Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. Arch Neurol 61:1515–1520PubMedCrossRefGoogle Scholar
  5. 5.
    Bieber A, Asakura K, Warrington A, Kaveri SV, Rodriguez M (2000) Antibody-mediated remyelination: relevance to multiple sclerosis. Mult Scler 6(Suppl 2):S1–S5PubMedCrossRefGoogle Scholar
  6. 6.
    Bjartmar C, Wujek JR, Trapp BD (2003) Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 206:165–171PubMedCrossRefGoogle Scholar
  7. 7.
    Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR. Early Treatment of Multiple Sclerosis Study Group (2001) Effect on early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576–1582PubMedCrossRefGoogle Scholar
  8. 8.
    Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290–297PubMedCrossRefGoogle Scholar
  9. 9.
    Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770–782PubMedCrossRefGoogle Scholar
  10. 10.
    Cook SD, Troiano R, Rohowsky-Kochan C, Jotkowitz A, Bielory L, Mehta PD, Oleske J, Bansil S, Dowling PC (1992) Intravenous gamma globulin in progressive MS. Acta Neurol Scand 86:171–175PubMedGoogle Scholar
  11. 11.
    Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O’Brien PC (1994) A plasma exchange versus immune globuline infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838–845PubMedCrossRefGoogle Scholar
  12. 12.
    Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B (1997) Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis.Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet 349:589–593PubMedCrossRefGoogle Scholar
  13. 13.
    Haas J, Maas-Enriquez M, Hartung HP (2005) Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis—results of a retrospective multicenter observational study over five years. Mult Scler 11:562–567PubMedCrossRefGoogle Scholar
  14. 14.
    Hommes OR, Sorensen PS, Fazekas F, Enriquez MM, Koelmel HW, Fernandez O, Pozilli C, O’Connor P (2004) Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. Lancet 364:1149–1156PubMedCrossRefGoogle Scholar
  15. 15.
    Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ, Simonian NA, Slasor PJ, Sandrock AW (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis: CHAMPS Study Group. N Engl J Med 343:898–904PubMedCrossRefGoogle Scholar
  16. 16.
    Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH et al. (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 39:285–294PubMedCrossRefGoogle Scholar
  17. 17.
    Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268–1276PubMedGoogle Scholar
  18. 18.
    Kappos L, Polman C, Freedman MS, Edan GC, Hartung HP, Miller DH, Montalban X, Barkhof F, Bauer L, Jakobs P, Sandbrink R on behalf of the BENEFIT Study Group (2005) Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): clinical results. Mult Scler (Suppl 1):10Google Scholar
  19. 19.
    Kieseier BC, Kiefer R, Gold R, Hemmer B, Willison HJ, Hartung HP (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30:131–156PubMedCrossRefGoogle Scholar
  20. 20.
    Koçer B, Yildirim-Gurel S, Tali ET, Irkec C, Isik S (2004) The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G. Neuroradiology 46:287–290PubMedCrossRefGoogle Scholar
  21. 21.
    Lewanska M, Siger-Zajdel M, Selmaj K (2002) No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment. Eur J Neurol 9:565–572PubMedCrossRefGoogle Scholar
  22. 22.
    MS-Therapie Konsensus Gruppe (1999) Immunomodulatorische Stufentherapie der multiplen Sklerose. Nervenarzt 70:371–386CrossRefGoogle Scholar
  23. 23.
    MS-Therapie Konsensus Gruppe (2000) Immunomodulatorische Stufentherapie der multiplen Sklerose. I. Ergänzung.Nervenarzt 72:150–157Google Scholar
  24. 24.
    MS-Therapie Konsensus Gruppe (2002) Immunmodulatorische Stupentherapie der multiplen Sklerose. Neue Aspekte und praktische Umsetzung. Nervenarzt 73:556–563CrossRefGoogle Scholar
  25. 25.
    Multiple Sclerosis Therapy Consensus Group (2004) Escalating immunotherapy of multiple sclerosis. J Neurol 251:1329–1339CrossRefGoogle Scholar
  26. 26.
    Murray PD, McGavern DB, Sathornsumetee S, Rodriguez M (2001) Spontaneous remyelination following extensive demyelination is associated with improved neurological function in a viral model of multiple sclerosis. Brain 124:1403–1416PubMedCrossRefGoogle Scholar
  27. 27.
    Noseworthy JH, O’Brien PC, Petterson TM, Weis J, Stevens L, Peterson WK, Sneve D, Cross SA, Leavitt JA, Auger RG, Weinshenker BG, Dodick DW, Wingerchuk DM, Rodriguez M (2001) A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 56:1514–1522PubMedGoogle Scholar
  28. 28.
    Noseworthy JH, O’Brien PC, Weinshenker BG, Weis JA, Petterson TM, Erickson BJ, Windebank AJ, Whisnant JP, Stolp-Smith KA, Harper CM Jr, Low PA, Romme LJ, Johnson M, An KN, Rodriguez M (2000) IV immunoglobulin does not reverse established weakness in MS. Neurology 55:1135–1143PubMedGoogle Scholar
  29. 29a.
    Pöhlau D, Federlein J, Postert T, Sailer M, Bethke F, Kappos L, Haas J, Przuntek H (1997) Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis—outline of a double-blind randomized, placebo-controlled trial. Mult Scler 3:149–152CrossRefGoogle Scholar
  30. 29b.
    Pöhlau D, Przuntek H, Späth P, Andresen I and the IVIG Study Group (2005) Intravenous immunoglobulin treatment for patients with primary or secondary progressive multiple sclerosis. Mult Scler (Suppl 1):163Google Scholar
  31. 30.
    PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504CrossRefGoogle Scholar
  32. 31.
    Prineas JW, Kwon EE, Cho E, Sharer LR, Barnett MH, Oleszak EL, Hoffman B, Morgan BP (2001) Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 50:646–657PubMedCrossRefGoogle Scholar
  33. 32.
    Rodriguez M, Lennon VA (1990) Immunoglobulins promote remyelination in the central nervous system. Ann Neurol 27:12–17PubMedCrossRefGoogle Scholar
  34. 33.
    Rodriguez M, Miller DJ, Lennon VA (1996) Immunoglobulins reactive with myelin basic protein promote CNS remyelination. Neurology 46:538–545PubMedGoogle Scholar
  35. 34.
    Roed HG, Langkilde A, Sellebjerg FT, Lauritzen M, Bang P, Morup A, Frederiksen JL (2005) A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 64:804–810PubMedGoogle Scholar
  36. 35.
    Rothfelder U, Neu I, Pelka R (1982) Therapy of multiple sclerosis with immunoglobulin G MMW Munch Med Wochenschr 124:74–78Google Scholar
  37. 36.
    Schuller E, Govaerts A (1983) First results of immunotherapy with immunoglobulin G in multiple sclerosis patients. Eur Neurol 22:205–212PubMedGoogle Scholar
  38. 37.
    Simone IL, Carrara D, Tortorella C, Ceccarelli A, Livrea P (2000) Early onset multiple sclerosis. Neurol Sci 21(4 Suppl 2):S861–S863PubMedCrossRefGoogle Scholar
  39. 38.
    Sorensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, Kirsmeier H, Larsen V, Lee ML (1998) Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis. Neurology 50:1273–1281PubMedGoogle Scholar
  40. 39.
    Sorensen PS, Fazekas F, Lee M (2002) Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Eur J Neurol 9:557–563PubMedCrossRefGoogle Scholar
  41. 40.
    Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M; TARIMS Study Group (2004) IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 63:2028–2033PubMedGoogle Scholar
  42. 41.
    Stangel M, Boegner F, Klatt CH, Hofmeister C, Seyfert S (2000) Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 68:89–92PubMedCrossRefGoogle Scholar
  43. 42.
    Stangel M, Gold R (2004) Use of IV immunoglobulins in neurology. Evidence-based consensus. Nervenarzt 75:801–815PubMedCrossRefGoogle Scholar
  44. 43.
    Stangel M, Hartung HP (2002) Despair of repair. J Neurol Neurosurg Psychiatry 72:1–4PubMedCrossRefGoogle Scholar
  45. 44.
    Teksam M, Tali T, Kocer B, Isik S (2000) Qualitative and quantitative volumetric evaluation of the efficacy of intravenous immunoglobulin in multiple sclerosis: preliminary report. Neuroradiology 42:885–889PubMedCrossRefGoogle Scholar
  46. 45.
    The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655–661Google Scholar
  47. 46.
    Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278–285PubMedCrossRefGoogle Scholar
  48. 47.
    van der Meche FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 326:1123–1129PubMedCrossRefGoogle Scholar
  49. 48.
    van Doorn PA, Vermeulen M, Brand A, Mulder PG, Busch HF (1991) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neur 48:217–220Google Scholar
  50. 49.
    Vermeulen M, Van Doorn PA, Brand A, Strengers PF, Jennekens FG, Busch HF (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36–39PubMedCrossRefGoogle Scholar
  51. 50.
    Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, Movig KL, Lenderink AW (2004) A randomized, double-blind, placebo-controlled pilot study of i. v. immune globulins in combination i.v methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 10:89–91PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff-Verlag 2006

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of RostockRostockGermany

Personalised recommendations